Compositions and methods for treating hemiplegic migraine

Abstract

This disclosure provides novel pharmaceutical formulations comprising CBD and THC, the manufacture of the same, and the use of the same for the treatment of hemiplegic migraine.

Claims

1. A pharmaceutical composition comprising CBD and THC, suitable for administration to a target requiring such CBD, wherein the weight ratio of CBD to THC is approximately 10:1 to approximately 400:

1.

2. The pharmaceutical composition according to claim 1, wherein the purity of THC and CBD is at least 90% by weight.

3. The pharmaceutical composition according to claim 1, wherein the weight ratio of CBD to THC is approximately 30:1 to approximately 300:

1.

4. The pharmaceutical composition according to claim 1, wherein the ratio of CBD to THC is approximately 25:1 to approximately 400:

1.

5. The pharmaceutical composition according to claim 1, wherein the ratio of CBD to THC is approximately 30:1 to approximately 100:

1.

6. The pharmaceutical composition according to claim 1, wherein the ratio of CBD to THC is approximately 33.3:

1.

7. The pharmaceutical composition according to claim 1, wherein the ratio of CBD to THC is approximately 50:

1.

8. The pharmaceutical composition according to claim 1, wherein the ratio of CBD to THC is approximately 60:

1.

9. The pharmaceutical composition according to claim 1, wherein the ratio of CBD to THC is approximately 66.7:

1.

10. The pharmaceutical composition according to claim 1, wherein the ratio of CBD to THC is approximately 70:

1.

11. The pharmaceutical composition according to claim 1, wherein the ratio of CBD to THC is approximately 80:

1.

12. The pharmaceutical composition according to claim 1, wherein the ratio of CBD to THC is approximately 90:

1.

13. The pharmaceutical composition according to claim 1, wherein the ratio of CBD to THC is approximately 100:

1.

14. The pharmaceutical composition according to claim 1, wherein the ratio of CBD to THC is approximately 125:

1.

15. The pharmaceutical composition according to claim 1, wherein the ratio of CBD to THC is approximately 150:

1.

16. The pharmaceutical composition according to claim 1, wherein the ratio of CBD to THC is approximately 200:

1.

17. The pharmaceutical composition according to claim 1, comprising approximately 0.1% to approximately 99% THC.

18. The pharmaceutical composition according to claim 1, comprising approximately 1% to approximately 99.9% CBD.

19. The pharmaceutical composition according to claim 1, further comprising a terpenoid.

20. The pharmaceutical composition according to claim 19, wherein the terpenoid comprises myrcene, β-caryophyllene, limonene, α-terpineol, linalool, α-phellandrene, α-pinene, β-pinene, γ-terpinene, nerolidol, phytol, caryophyllene oxide, or α-humul.

21. The pharmaceutical composition according to claim 1, further comprising an analgesic.

22. The pharmaceutical composition according to claim 21, wherein the analgesic comprises paracetamol, acetaminophen, a nonsteroidal anti-inflammatory drug, a 5-HT (serotonin) receptor agonist, a calcitonin gene-related peptide (CGRP) receptor antagonist, a D-aspartate N-methyl (NMDA) inhibitor, a glutamate receptor antagonist, a substance P inhibitor, a GABA inhibitor, a FAAH inhibitor, a nerve growth factor (NGF) inhibitor, a brain-derived neurotrophic factor (BDNF) inhibitor, an extracellular signal-regulated kinase (ERK) antagonist, or an NO inhibitor.

23. The pharmaceutical composition according to claim 1, further comprising at least one minor cannabinoid.

24. The pharmaceutical composition according to claim 23, wherein at least one minor cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.

25. The pharmaceutical composition according to claim 23, wherein the purity of at least one minor cannabinoid is at least 90% by weight.

26. The pharmaceutical composition according to claim 1, further comprising a pharmaceutically acceptable excipient.

27. The pharmaceutical composition according to claim 26, wherein the pharmaceutically acceptable excipients include diluents, binders, fillers, buffers, pH adjusters, disintegrants, dispersants, preservatives, lubricants, flavor masking agents, fragrances, or colorants.

28. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is suitable for administration by injection.

29. The pharmaceutical composition according to claim 1, wherein the ratio of CBD to THC is approximately 50:1 to approximately 150:

1.

30. The pharmaceutical composition according to claim 1, wherein the ratio of CBD to THC is approximately 75:1 to approximately 125:

1.

31. A pharmaceutical composition according to claim 1, suitable for sublingual administration.

32. The composition according to claim 31, wherein the pharmaceutical composition is a liquid solution suitable for administration as a spray.

33. A pharmaceutical composition according to claim 1, suitable for inhalation administration.

34. The pharmaceutical composition according to claim 1, wherein the composition contains no more than 500 mg of CBD in its maximum dose.

35. The pharmaceutical composition according to claim 1, comprising no more than 5 mg of THC in the maximum dose.

36. A pharmaceutical composition suitable for injection, comprising CBD and THC, wherein the weight ratio of CBD to THC is about 30:1 to about 300:

1.

37. The pharmaceutical composition according to claim 36, wherein the purity of THC and CBD is at least 90% by weight.

38. The pharmaceutical composition according to claim 36, wherein the ratio of CBD to THC is approximately 30:1 to approximately 100:

1.

39. The pharmaceutical composition according to claim 36, wherein the ratio of CBD to THC is approximately 50:

1.

40. The pharmaceutical composition according to claim 36, wherein the ratio of CBD to THC is approximately 60:

1.

41. The pharmaceutical composition according to claim 36, wherein the ratio of CBD to THC is approximately 70:

1.

42. The pharmaceutical composition according to claim 36, wherein the ratio of CBD to THC is approximately 80:

1.

43. The pharmaceutical composition according to claim 36, wherein the ratio of CBD to THC is approximately 90:

1.

44. The pharmaceutical composition according to claim 36, wherein the ratio of CBD to THC is approximately 100:

1.

45. The pharmaceutical composition according to claim 36, wherein the ratio of CBD to THC is approximately 125:

1.

46. The pharmaceutical composition according to claim 36, wherein the ratio of CBD to THC is approximately 150:

1.

47. The pharmaceutical composition according to claim 36, wherein the ratio of CBD to THC is approximately 200:

1.

48. The pharmaceutical composition according to claim 36, wherein the composition contains about 0.1% to about 99% THC.

49. The pharmaceutical composition according to claim 36, wherein the composition contains about 1% to about 99.9% CBD.

50. The pharmaceutical composition according to claim 36, further comprising a terpenoid.

51. The pharmaceutical composition according to claim 50, wherein the terpenoid comprises myrcene, β-caryophyllene, limonene, α-terpineol, linalool, α-phellandrene, α-pinene, β-pinene, γ-terpinene, nerolidol, phytol, caryophyllene oxide, or α-humul.

52. The pharmaceutical composition according to claim 36, further comprising an analgesic.

53. The pharmaceutical composition according to claim 52, wherein the analgesic comprises paracetamol, acetaminophen, a nonsteroidal anti-inflammatory drug, a 5-HT (serotonin) receptor agonist, a calcitonin gene-related peptide (CGRP) receptor antagonist, a D-aspartate N-methyl (NMDA) inhibitor, a glutamate receptor antagonist, a substance P inhibitor, a GABA inhibitor, a FAAH inhibitor, a nerve growth factor (NGF) inhibitor, a brain-derived neurotrophic factor (BDNF) inhibitor, an extracellular signal-regulated kinase (ERK) antagonist, or an NO inhibitor.

54. The pharmaceutical composition according to claim 36, further comprising at least one minor cannabinoid.

55. The pharmaceutical composition according to claim 54, wherein at least one minor cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.

56. The pharmaceutical composition according to claim 55, wherein the purity of at least one minor cannabinoid is at least 90% by weight.

57. The pharmaceutical composition according to claim 36, further comprising a pharmaceutically acceptable excipient.

58. The pharmaceutical composition according to claim 57, wherein the pharmaceutically acceptable excipients include a carrier, diluent, binder, filler, buffer, pH modifier, disintegrant, dispersant, preservative, lubricant, taste masking agent, fragrance, or colorant.

59. The pharmaceutical composition according to claim 36, wherein the ratio of CBD to THC is approximately 50:1 to approximately 150:

1.

60. The pharmaceutical composition according to claim 36, wherein the ratio of CBD to THC is approximately 75:1 to approximately 125:

1.

61. A pharmaceutical composition comprising at least one minor cannabinoid, CBD, and THC, suitable for administration to a target requiring such treatment.

62. The pharmaceutical composition according to claim 61, wherein at least one minor cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.

63. The pharmaceutical composition according to claim 61, wherein the purity of at least one minor cannabinoid is at least 90% by weight.

64. The pharmaceutical composition according to claim 61, wherein the weight ratio of CBD to THC is approximately 10:1 to approximately 300:

1.

65. The pharmaceutical composition according to claim 61, wherein the purity of THC and CBD is at least 90% by weight.

66. The pharmaceutical composition according to claim 61, further comprising a terpenoid.

67. The pharmaceutical composition according to claim 66, wherein the terpenoid comprises myrcene, β-caryophyllene, limonene, α-terpineol, linalool, α-phellandrene, α-pinene, β-pinene, γ-terpinene, nerolidol, phytol, caryophyllene oxide, or α-humul.

68. The pharmaceutical composition according to claim 61, further comprising an analgesic.

69. The pharmaceutical composition according to claim 68, wherein the analgesic comprises paracetamol, acetaminophen, a nonsteroidal anti-inflammatory drug, a 5-HT (serotonin) receptor agonist, a calcitonin gene-related peptide (CGRP) receptor antagonist, a D-aspartate N-methyl (NMDA) inhibitor, a glutamate receptor antagonist, a substance P inhibitor, a GABA inhibitor, a FAAH inhibitor, a nerve growth factor (NGF) inhibitor, a brain-derived neurotrophic factor (BDNF) inhibitor, an extracellular signal-regulated kinase (ERK) antagonist, or an NO inhibitor.

70. The pharmaceutical composition according to claim 61, wherein the ratio of CBD to THC is approximately 30:1 to approximately 100:

1.

71. The pharmaceutical composition according to claim 61, wherein the ratio of CBD to THC is approximately 50:

1.

72. The pharmaceutical composition according to claim 61, wherein the ratio of CBD to THC is approximately 60:

1.

73. The pharmaceutical composition according to claim 61, wherein the ratio of CBD to THC is approximately 70:

1.

74. The pharmaceutical composition according to claim 61, wherein the ratio of CBD to THC is approximately 80:

1.

75. The pharmaceutical composition according to claim 61, wherein the ratio of CBD to THC is approximately 90:

1.

76. The pharmaceutical composition according to claim 61, wherein the ratio of CBD to THC is approximately 100:

1.

77. The pharmaceutical composition according to claim 61, wherein the ratio of CBD to THC is approximately 125:

1.

78. The pharmaceutical composition according to claim 61, wherein the ratio of CBD to THC is approximately 150:

1.

79. The pharmaceutical composition according to claim 61, wherein the ratio of CBD to THC is approximately 200:

1.

80. The pharmaceutical composition according to claim 61, further comprising a pharmaceutically acceptable excipient.

81. The pharmaceutical composition according to claim 80, wherein the pharmaceutically acceptable excipients include a carrier, diluent, binder, filler, buffer, pH modifier, disintegrant, dispersant, preservative, lubricant, taste masking agent, fragrance, or colorant.

82. The pharmaceutical composition according to claim 81, suitable for administration by injection.

83. The pharmaceutical composition according to claim 61, wherein the ratio of CBD to THC is approximately 50:1 to approximately 150:

1.

84. The pharmaceutical composition according to claim 61, wherein the ratio of CBD to THC is approximately 75:1 to approximately 125:

1.

85. A pharmaceutical composition suitable for injection, comprising at least one minor cannabinoid, CBD, and THC.

86. The pharmaceutical composition according to claim 85, wherein at least one minor cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.

87. The pharmaceutical composition according to claim 85, wherein the purity of at least one minor cannabinoid is at least 90% by weight.

88. The pharmaceutical composition according to claim 85, wherein the weight ratio of CBD to THC is approximately 10:1 to approximately 300:

1.

89. The pharmaceutical composition according to claim 85, wherein the purity of THC and CBD is at least 90% by weight.

90. The pharmaceutical composition according to claim 85, further comprising a terpenoid.

91. The pharmaceutical composition according to claim 90, wherein the terpenoid comprises myrcene, β-caryophyllene, limonene, α-terpineol, linalool, α-phellandrene, α-pinene, β-pinene, γ-terpinene, nerolidol, phytol, caryophyllene oxide, or α-humul.

92. The pharmaceutical composition according to claim 85, further comprising an analgesic.

93. The pharmaceutical composition according to claim 92, wherein the analgesic comprises paracetamol, acetaminophen, a nonsteroidal anti-inflammatory drug, a 5-HT (serotonin) receptor agonist, a calcitonin gene-related peptide (CGRP) receptor antagonist, a D-aspartate N-methyl (NMDA) inhibitor, a glutamate receptor antagonist, a substance P inhibitor, a GABA inhibitor, a FAAH inhibitor, a nerve growth factor (NGF) inhibitor, a brain-derived neurotrophic factor (BDNF) inhibitor, an extracellular signal-regulated kinase (ERK) antagonist, or an NO inhibitor.

94. The pharmaceutical composition according to claim 85, wherein the ratio of CBD to THC is approximately 30:1 to approximately 100:

1.

95. The pharmaceutical composition according to claim 85, wherein the ratio of CBD to THC is approximately 50:

1.

96. The pharmaceutical composition according to claim 85, wherein the ratio of CBD to THC is approximately 60:

1.

97. The pharmaceutical composition according to claim 85, wherein the ratio of CBD to THC is approximately 70:

1.

98. The pharmaceutical composition according to claim 85, wherein the ratio of CBD to THC is approximately 80:

1.

99. The pharmaceutical composition according to claim 85, wherein the ratio of CBD to THC is approximately 90:

1.

100. The pharmaceutical composition according to claim 85, wherein the ratio of CBD to THC is approximately 100:

1.

101. The pharmaceutical composition according to claim 85, wherein the ratio of CBD to THC is approximately 125:

1.

102. The pharmaceutical composition according to claim 85, wherein the ratio of CBD to THC is approximately 150:

1.

103. The pharmaceutical composition according to claim 85, wherein the ratio of CBD to THC is approximately 200:

1.

104. The pharmaceutical composition according to claim 85, further comprising a pharmaceutically acceptable excipient.

105. The pharmaceutical composition according to claim 104, wherein the pharmaceutically acceptable excipients include a carrier, diluent, binder, filler, buffer, pH modifier, disintegrant, dispersant, preservative, lubricant, taste masking agent, fragrance, or colorant.

106. The pharmaceutical composition according to claim 85, wherein the ratio of CBD to THC is approximately 50:1 to approximately 150:

1.

107. The pharmaceutical composition according to claim 85, wherein the ratio of CBD to THC is approximately 75:1 to approximately 125:

1.

108. A method for treating the pain of acute migraine, comprising administering a pharmaceutical composition containing CBD and THC to a subject in need thereof.

109. The method according to claim 108, wherein the subject has chronic migraine.

110. The method according to claim 108, wherein the subject has frequent migraines.

111. The method according to claim 108, wherein administration is achieved by injection.

112. The method according to claim 108, wherein the treatment is effective within at least two hours after administration.

113. The method according to claim 108, wherein the pain of acute migraine is measured by a pain scale.

114. The method according to claim 108, wherein at least one biomarker for central and peripheral sensitization is regulated as a result of administration.

115. The method according to claim 114, wherein at least one biomarker is selected from the group consisting of NMDA, glutamate, CGRP, FAAH, substance P, 5-HT, NO, GABA, NGF, serotonin, dopamine, AEA, and 2-AG.

116. The method according to claim 108, wherein the pharmaceutical composition comprises an amount of CBD effective in reducing the undesirable side effects of THC.

117. The method according to claim 116, wherein the undesirable side effects of THC include psychoactivity, psychosis, anxiety, paranoia, dizziness, confusion, cardiovascular risk, memory impairment, or a combination thereof.

118. The method according to claim 108, wherein the weight ratio of CBD to THC is approximately 10:1 to approximately 300:

1.

119. The method according to claim 108, wherein the weight ratio of CBD to THC is approximately 30:1 to approximately 100:

1.

120. The method according to claim 108, wherein the weight ratio of CBD to THC is approximately 30:

1.

121. The method according to claim 108, wherein the weight ratio of CBD to THC is approximately 50:

1.

122. The method according to claim 108, wherein the weight ratio of CBD to THC is approximately 75:

1.

123. The method according to claim 108, wherein the weight ratio of CBD to THC is approximately 100:

1.

124. The method according to claim 108, wherein the subject is a human.

125. The method according to claim 108, wherein the pharmaceutical composition further comprises a terpenoid.

126. The method according to claim 125, wherein the terpenoid comprises myrcene, β-caryophyllene, limonene, α-terpineol, linalool, α-phellandrene, α-pinene, β-pinene, γ-terpinene, nerolidol, phytol, caryophyllene oxide, or α-humul.

127. The method according to claim 108, wherein the pharmaceutical composition further comprises an analgesic.

128. The method according to claim 127, wherein the analgesic comprises paracetamol, acetaminophen, a nonsteroidal anti-inflammatory drug, a 5-HT (serotonin) receptor agonist, a calcitonin gene-related peptide (CGRP) receptor antagonist, a D-aspartate N-methyl (NMDA) inhibitor, a glutamate receptor antagonist, a substance P inhibitor, a GABA inhibitor, a FAAH inhibitor, a nerve growth factor (NGF) inhibitor, a brain-derived neurotrophic factor (BDNF) inhibitor, an extracellular signal-regulated kinase (ERK) antagonist, or an NO inhibitor.

129. The method according to claim 108, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

130. The method according to claim 129, wherein the pharmaceutically acceptable excipients include carriers, diluents, binders, fillers, buffers, pH modifiers, disintegrants, dispersants, preservatives, lubricants, taste masking agents, fragrances, or colorants.

131. The method according to claim 108, wherein the purity of THC and CBD is at least 90% by weight.

132. The method according to claim 108, wherein the pharmaceutical composition further comprises at least one minor cannabinoid.

133. The method according to claim 132, wherein at least one minor cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.

134. The method according to claim 132, wherein the purity of at least one minor cannabinoid is at least 90% by weight.

135. The method according to claim 108, wherein the weight ratio of CBD to THC is approximately 50:1 to approximately 150:

1.

136. The method according to claim 108, wherein the weight ratio of CBD to THC is approximately 75:1 to approximately 125:

1.

137. A method for treating the pain of acute migraine, comprising administering a pharmaceutical composition comprising at least one minor cannabinoid, CBD, and THC to a subject in need thereof.

138. The method according to claim 137, wherein the subject has chronic migraine.

139. The method according to claim 137, wherein the subject has frequent migraines.

140. The method according to claim 137, wherein administration is achieved by injection.

141. The method according to claim 137, wherein the treatment is effective within at least two hours after administration.

142. The method according to claim 137, wherein the pain of acute migraine is measured by a pain scale.

143. The method according to claim 137, wherein at least one biomarker for central and peripheral sensitization is regulated as a result of administration.

144. The method according to claim 143, wherein at least one biomarker is selected from the group consisting of NMDA, glutamate, CGRP, FAAH, substance P, 5-HT, NO, GABA, NGF, serotonin, dopamine, AEA, and 2-AG.

145. The method according to claim 137, wherein the pharmaceutical composition comprises an amount of CBD effective in reducing the undesirable side effects of THC.

146. The method according to claim 137, wherein the undesirable side effects of THC include psychoactivity, psychosis, anxiety, paranoia, dizziness, confusion, cardiovascular risk, memory impairment, or a combination thereof.

147. The method according to claim 137, wherein the weight ratio of CBD to THC is approximately 10:1 to approximately 300:

1.

148. The method according to claim 137, wherein the weight ratio of CBD to THC is approximately 30:1 to approximately 100:

1.

149. The method according to claim 137, wherein the weight ratio of CBD to THC is approximately 30:

1.

150. The method according to claim 137, wherein the weight ratio of CBD to THC is approximately 50:

1.

151. The method according to claim 137, wherein the weight ratio of CBD to THC is approximately 75:

1.

152. The method according to claim 137, wherein the weight ratio of CBD to THC is approximately 100:

1.

153. The method according to claim 137, wherein the subject is a human.

154. The method according to claim 137, wherein the pharmaceutical composition further comprises a terpenoid.

155. The method according to claim 154, wherein the terpenoid comprises myrcene, β-caryophyllene, limonene, α-terpineol, linalool, α-phellandrene, α-pinene, β-pinene, γ-terpinene, nerolidol, phytol, caryophyllene oxide, or α-humul.

156. The method according to claim 137, wherein the pharmaceutical composition further comprises an analgesic.

157. The method according to claim 156, wherein the analgesic comprises paracetamol, acetaminophen, a nonsteroidal anti-inflammatory drug, a 5-HT (serotonin) receptor agonist, a calcitonin gene-related peptide (CGRP) receptor antagonist, a D-aspartate N-methyl (NMDA) inhibitor, a glutamate receptor antagonist, a substance P inhibitor, a GABA inhibitor, a FAAH inhibitor, a nerve growth factor (NGF) inhibitor, a brain-derived neurotrophic factor (BDNF) inhibitor, an extracellular signal-regulated kinase (ERK) antagonist, or an NO inhibitor.

158. The method according to claim 137, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

159. The method according to claim 158, wherein the pharmaceutically acceptable excipients include carriers, diluents, binders, fillers, buffers, pH modifiers, disintegrants, dispersants, preservatives, lubricants, taste masking agents, fragrances, or colorants.

160. The method according to claim 137, wherein the purity of THC and CBD is at least 90% by weight.

161. The method according to claim 137, wherein at least one minor cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.

162. The method according to claim 137, wherein the purity of at least one minor cannabinoid is at least 90% by weight.

163. The method according to claim 137, wherein the weight ratio of CBD to THC is approximately 50:1 to approximately 150:

1.

164. The method according to claim 137, wherein the weight ratio of CBD to THC is approximately 75:1 to approximately 125:

1.

165. A method for alleviating the pain of acute migraine, comprising administering a pharmaceutical composition comprising at least one minor cannabinoid, CBD, and THC to a subject in need thereof.

166. The method according to claim 165, wherein the subject has chronic migraine.

167. The method according to claim 165, wherein the subject has frequent migraines.

168. The method according to claim 165, wherein administration is achieved by injection.

169. The method according to claim 165, wherein the treatment is effective within at least two hours after administration.

170. The method according to claim 165, wherein the pain of acute migraine is measured by a pain scale.

171. The method according to claim 165, wherein at least one biomarker for central and peripheral sensitization is regulated as a result of administration.

172. The method according to claim 171, wherein at least one biomarker is selected from the group consisting of NMDA, glutamate, CGRP, FAAH, substance P, 5-HT, NO, GABA, NGF, serotonin, dopamine, AEA, and 2-AG.

173. The method according to claim 165, wherein the pharmaceutical composition comprises an amount of CBD effective in reducing the undesirable side effects of THC.

174. The method according to claim 173, wherein the undesirable side effects of THC include psychoactivity, psychosis, anxiety, paranoia, dizziness, confusion, cardiovascular risk, memory impairment, or a combination thereof.

175. The method according to claim 165, wherein the weight ratio of CBD to THC is approximately 10:1 to approximately 300:

1.

176. The method according to claim 165, wherein the weight ratio of CBD to THC is approximately 30:1 to approximately 100:

1.

177. The method according to claim 165, wherein the weight ratio of CBD to THC is approximately 30:

1.

178. The method according to claim 165, wherein the weight ratio of CBD to THC is approximately 50:

1.

179. The method according to claim 165, wherein the weight ratio of CBD to THC is approximately 75:

1.

180. The method according to claim 165, wherein the weight ratio of CBD to THC is approximately 100:

1.

181. The method according to claim 165, wherein the subject is a human.

182. The method according to claim 165, wherein the pharmaceutical composition further comprises a terpenoid.

183. The method according to claim 182, wherein the terpenoid comprises myrcene, β-caryophyllene, limonene, α-terpineol, linalool, α-phellandrene, α-pinene, β-pinene, γ-terpinene, nerolidol, phytol, caryophyllene oxide, or α-humul.

184. The method according to claim 165, wherein the pharmaceutical composition further comprises an analgesic.

185. The method according to claim 184, wherein the analgesic comprises paracetamol, acetaminophen, a nonsteroidal anti-inflammatory drug, a 5-HT (serotonin) receptor agonist, a calcitonin gene-related peptide (CGRP) receptor antagonist, a D-aspartate N-methyl (NMDA) inhibitor, a glutamate receptor antagonist, a substance P inhibitor, a GABA inhibitor, a FAAH inhibitor, a nerve growth factor (NGF) inhibitor, a brain-derived neurotrophic factor (BDNF) inhibitor, an extracellular signal-regulated kinase (ERK) antagonist, or an NO inhibitor.

186. The method according to claim 165, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

187. The method according to claim 186, wherein the pharmaceutically acceptable excipients include carriers, diluents, binders, fillers, buffers, pH modifiers, disintegrants, dispersants, preservatives, lubricants, taste masking agents, fragrances, or colorants.

188. The method according to claim 165, wherein the purity of THC and CBD is at least 90% by weight.

189. The method according to claim 165, wherein the pharmaceutical composition further comprises at least one minor cannabinoid.

190. The method according to claim 189, wherein at least one minor cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.

191. The method according to claim 189, wherein the purity of at least one minor cannabinoid is at least 90% by weight.

192. The method according to claim 165, wherein the weight ratio of CBD to THC is approximately 50:1 to approximately 150:

1.

193. The method according to claim 165, wherein the weight ratio of CBD to THC is approximately 75:1 to approximately 125:

1.

194. A method for alleviating the pain of acute migraine, comprising administering a pharmaceutical composition comprising at least one minor cannabinoid, CBD, and THC to a subject in need thereof.

195. The method according to claim 194, wherein the subject has chronic migraine.

196. The method according to claim 194, wherein the subject has frequent migraines.

197. The method according to claim 194, wherein administration is achieved by injection.

198. The method according to claim 194, wherein the treatment is effective within at least two hours after administration.

199. The method according to claim 194, wherein the pain of acute migraine is measured by a pain scale.

200. The method according to claim 194, wherein at least one biomarker for central and peripheral sensitization is regulated as a result of administration.

201. The method according to claim 200, wherein at least one biomarker is selected from the group consisting of NMDA, glutamate, CGRP, FAAH, substance P, 5-HT, NO, GABA, NGF, serotonin, dopamine, AEA, and 2-AG.

202. The method according to claim 194, wherein the pharmaceutical composition comprises an amount of CBD effective in reducing the undesirable side effects of THC.

203. The method according to claim 202, wherein the undesirable side effects of THC include psychoactivity, psychosis, anxiety, paranoia, dizziness, confusion, cardiovascular risk, memory impairment, or a combination thereof.

204. The method according to claim 194, wherein the weight ratio of CBD to THC is approximately 10:1 to approximately 300:

1.

205. The method according to claim 194, wherein the weight ratio of CBD to THC is approximately 30:1 to approximately 100:

1.

206. The method according to claim 194, wherein the weight ratio of CBD to THC is approximately 30:

1.

207. The method according to claim 194, wherein the weight ratio of CBD to THC is approximately 50:

1.

208. The method according to claim 194, wherein the weight ratio of CBD to THC is approximately 75:

1.

209. The method according to claim 194, wherein the weight ratio of CBD to THC is approximately 100:

1.

210. The method according to claim 194, wherein the subject is a human.

211. The method according to claim 194, wherein the pharmaceutical composition further comprises a terpenoid.

212. The method according to claim 211, wherein the terpenoid comprises myrcene, β-caryophyllene, limonene, α-terpineol, linalool, α-phellandrene, α-pinene, β-pinene, γ-terpinene, nerolidol, phytol, caryophyllene oxide, or α-humul.

213. The method according to claim 194, wherein the pharmaceutical composition further comprises an analgesic.

214. The method according to claim 213, wherein the analgesic comprises paracetamol, acetaminophen, a nonsteroidal anti-inflammatory drug, a 5-HT (serotonin) receptor agonist, a calcitonin gene-related peptide (CGRP) receptor antagonist, a D-aspartate N-methyl (NMDA) inhibitor, a glutamate receptor antagonist, a substance P inhibitor, a GABA inhibitor, a FAAH inhibitor, a nerve growth factor (NGF) inhibitor, a brain-derived neurotrophic factor (BDNF) inhibitor, an extracellular signal-regulated kinase (ERK) antagonist, or an NO inhibitor.

215. The method according to claim 194, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

216. The method according to claim 215, wherein the pharmaceutically acceptable excipients include carriers, diluents, binders, fillers, buffers, pH modifiers, disintegrants, dispersants, preservatives, lubricants, taste masking agents, fragrances, or colorants.

217. The method according to claim 194, wherein the purity of THC and CBD is at least 90% by weight.

218. The method according to claim 194, wherein at least one minor cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.

219. The method according to claim 194, wherein the purity of at least one minor cannabinoid is at least 90% by weight.

220. The method according to claim 194, wherein the weight ratio of CBD to THC is approximately 50:1 to approximately 150:

1.

221. The method according to claim 194, wherein the weight ratio of CBD to THC is approximately 75:1 to approximately 125:

1.

222. A method for reducing spontaneous pain, comprising administering a pharmaceutical composition comprising at least one minor cannabinoid, CBD, and THC to a subject in need thereof.

223. The method according to claim 222, wherein spontaneous pain is measured by facial grimace.

224. The method according to claim 222, wherein the subject is male.

225. The method according to claim 222, wherein the subject is a human.

226. The method according to claim 222, wherein the weight ratio of CBD to THC is at least about 50:

1.

227. The method according to claim 222, wherein the ratio of CBD to THC is at least about 75:

1.

228. The method according to claim 222, wherein the ratio of CBD to THC is at least about 100:

1.

229. The method according to claim 222, wherein the ratio of CBD to THC is approximately 50:1 to approximately 300:

1.

230. The method according to claim 222, wherein the ratio of CBD to THC is approximately 50:1 to approximately 200:

1.

231. The method according to claim 222, wherein the ratio of CBD to THC is approximately 50:1 to approximately 150:

1.

232. The method according to claim 222, wherein the ratio of CBD to THC is approximately 75:1 to approximately 125:

1.

233. The method according to claim 222, wherein administration is achieved via injection.

234. The method according to claim 222, wherein the treatment is effective within at least two hours after administration.

235. The method according to claim 222, wherein the pharmaceutical composition further comprises a terpenoid.

236. The method according to claim 235, wherein the terpenoid comprises myrcene, β-caryophyllene, limonene, α-terpineol, linalool, α-phellandrene, α-pinene, β-pinene, γ-terpinene, nerolidol, phytol, caryophyllene oxide, or α-humul.

237. The method according to claim 222, wherein the pharmaceutical composition further comprises an analgesic.

238. The method according to claim 237, wherein the analgesic comprises paracetamol, acetaminophen, a nonsteroidal anti-inflammatory drug, a 5-HT (serotonin) receptor agonist, a calcitonin gene-related peptide (CGRP) receptor antagonist, a D-aspartate N-methyl (NMDA) inhibitor, a glutamate receptor antagonist, a substance P inhibitor, a GABA inhibitor, a FAAH inhibitor, a nerve growth factor (NGF) inhibitor, a brain-derived neurotrophic factor (BDNF) inhibitor, an extracellular signal-regulated kinase (ERK) antagonist, or an NO inhibitor.

239. The method according to claim 222, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

240. The method according to claim 239, wherein the pharmaceutically acceptable excipients include carriers, diluents, binders, fillers, buffers, pH modifiers, disintegrants, dispersants, preservatives, lubricants, taste masking agents, fragrances, or colorants.

241. The method according to claim 222, wherein the purity of THC and CBD is at least 90% by weight.

242. The method according to claim 222, wherein at least one minor cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CDC, and D8-THC.

243. The method according to claim 222, wherein the purity of at least one minor cannabinoid is at least 90% by weight.

244. The method according to claim 222, wherein the weight ratio of CBD to THC is approximately 50:1 to approximately 150:

1.

245. The method according to claim 222, wherein the weight ratio of CBD to THC is approximately 75:1 to approximately 125:

1.

246. A method for treating hemiplegic migraine, comprising administering a pharmaceutical composition comprising at least one minor cannabinoid, CBD, and THC to a subject in need thereof.

247. The method according to claim 246, wherein the subject is male.

248. The method according to claim 246, wherein the subject is a human.

249. The method according to claim 246, wherein administration is achieved by injection.

250. The method according to claim 246, wherein treatment is effective when administered within at least two hours.

251. The method according to claim 246, wherein the pharmaceutical composition further comprises a terpenoid.

252. The method according to claim 251, wherein the terpenoid comprises myrcene, β-caryophyllene, limonene, α-terpineol, linalool, α-phellandrene, α-pinene, β-pinene, γ-terpinene, nerolidol, phytol, caryophyllene oxide, or α-humul.

253. The method according to claim 246, wherein the pharmaceutical composition further comprises an analgesic.

254. The method according to claim 253, wherein the analgesic comprises paracetamol, acetaminophen, a nonsteroidal anti-inflammatory drug, a 5-HT (serotonin) receptor agonist, a calcitonin gene-related peptide (CGRP) receptor antagonist, a D-aspartate N-methyl (NMDA) inhibitor, a glutamate receptor antagonist, a substance P inhibitor, a GABA inhibitor, a FAAH inhibitor, a nerve growth factor (NGF) inhibitor, a brain-derived neurotrophic factor (BDNF) inhibitor, an extracellular signal-regulated kinase (ERK) antagonist, or an NO inhibitor.

255. The method according to claim 246, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

256. The method according to claim 255, wherein the pharmaceutically acceptable excipients include carriers, diluents, binders, fillers, buffers, pH modifiers, disintegrants, dispersants, preservatives, lubricants, taste masking agents, fragrances, or colorants.

257. The method according to claim 246, wherein the purity of THC and CBD is at least 90% by weight.

258. The method according to claim 246, wherein the pharmaceutical composition further comprises at least one minor cannabinoid.

259. The method according to claim 258, wherein at least one minor cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.

260. The method according to claim 258, wherein the purity of at least one minor cannabinoid is at least 90% by weight.

261. The method according to claim 246, wherein the weight ratio of CBD to THC is approximately 50:1 to approximately 150:

1.

262. The method according to claim 246, wherein the weight ratio of CBD to THC is approximately 75:1 to approximately 125:

1.

263. The method according to claim 246, wherein the hemiplegic migraine is familial hemiplegic migraine.

264. The method according to claim 246, wherein the hemiplegic migraine is sporadic hemiplegic migraine.

265. The method according to claim 246, wherein the pharmaceutical composition is administered when the patient develops the first signs of an acute attack of hemiplegic migraine.

266. The method according to claim 246, wherein the pharmaceutical composition is administered within 5 minutes of the onset of the first signs of an acute attack of hemiplegic migraine.

267. The method according to claim 246, wherein the pharmaceutical composition is administered within 10 minutes of the onset of the first signs of an acute attack of hemiplegic migraine.

268. The method according to claim 246, wherein the pharmaceutical composition is administered within 30 minutes of the onset of the first signs of an acute attack of hemiplegic migraine.

269. The method according to claim 246, wherein the pharmaceutical composition is administered within one hour of the onset of the first signs of an acute attack of hemiplegic migraine.

270. The method according to claim 246, wherein the pharmaceutical composition is administered within two hours of the onset of the first signs of an acute attack of hemiplegic migraine.

271. The method according to claim 246, wherein the pharmaceutical composition is administered within four hours of the onset of the first signs of an acute attack of hemiplegic migraine.

272. The method according to claim 246, further comprising administering a second dose of the pharmaceutical composition at least 90 minutes after the first dose.

273. The method according to claim 272, wherein no more than two doses are administered within a 24-hour period.

274. The method according to claim 246, wherein the subject does not experience headache pain within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

275. The method according to claim 246, wherein the subject experiences relief of headache pain within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

276. The method according to claim 246, wherein the subject experiences a reduction in phonophobia within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

277. The method according to claim 246, wherein the subject experiences a reduction in nausea within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

278. The method according to claim 246, wherein the subject does not experience headache pain for two hours or more after administration.

279. The method according to claim 246, wherein the subject does not have hemiplegia within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

280. The method according to claim 246, wherein the subject experiences a reduction in arm hemiplegia within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

281. The method according to claim 246, wherein the subject experiences a reduction in leg hemiplegia within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

282. A method for treating familial hemiplegic migraine, comprising administering a pharmaceutical composition comprising at least one minor cannabinoid, CBD, and THC to a subject requiring such treatment.

283. The method according to claim 282, wherein the subject is male.

284. The method according to claim 282, wherein the subject is a human.

285. The method according to claim 282, wherein administration is achieved by injection.

286. The method according to claim 282, wherein the treatment is effective within at least two hours after administration.

287. The method according to claim 282, wherein the pharmaceutical composition further comprises a terpenoid.

288. The method according to claim 287, wherein the terpenoid comprises myrcene, β-caryophyllene, limonene, α-terpineol, linalool, α-phellandrene, α-pinene, β-pinene, γ-terpinene, nerolidol, phytol, caryophyllene oxide, or α-humul.

289. The method according to claim 282, wherein the pharmaceutical composition further comprises an analgesic.

290. The method according to claim 289, wherein the analgesic comprises paracetamol, acetaminophen, a nonsteroidal anti-inflammatory drug, a 5-HT (serotonin) receptor agonist, a calcitonin gene-related peptide (CGRP) receptor antagonist, a D-aspartate N-methyl (NMDA) inhibitor, a glutamate receptor antagonist, a substance P inhibitor, a GABA inhibitor, a FAAH inhibitor, a nerve growth factor (NGF) inhibitor, a brain-derived neurotrophic factor (BDNF) inhibitor, an extracellular signal-regulated kinase (ERK) antagonist, or an NO inhibitor.

291. The method according to claim 282, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

292. The method according to claim 291, wherein the pharmaceutically acceptable excipients include carriers, diluents, binders, fillers, buffers, pH modifiers, disintegrants, dispersants, preservatives, lubricants, taste masking agents, fragrances, or colorants.

293. The method according to claim 282, wherein the purity of THC and CBD is at least 90% by weight.

294. The method according to claim 282, wherein the pharmaceutical composition further comprises at least one minor cannabinoid.

295. The method according to claim 294, wherein at least one minor cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.

296. The method according to claim 294, wherein the purity of at least one minor cannabinoid is at least 90% by weight.

297. The method according to claim 282, wherein the weight ratio of CBD to THC is approximately 50:1 to approximately 150:

1.

298. The method according to claim 282, wherein the weight ratio of CBD to THC is approximately 75:1 to approximately 125:

1.

299. The method according to claim 282, wherein familial hemiplegic migraine is familial hemiplegic migraine type 1.

300. The method according to claim 282, wherein familial hemiplegic migraine is familial hemiplegic migraine type 2.

301. The method according to claim 282, wherein the familial hemiplegic migraine is familial hemiplegic migraine type 3.

302. The method according to claim 282, wherein the pharmaceutical composition is administered when the first signs of an acute attack of familial hemiplegic migraine develop.

303. The method according to claim 282, wherein the pharmaceutical composition is administered within 5 minutes of the onset of the first signs of an acute attack of familial hemiplegic migraine.

304. The method according to claim 282, wherein the pharmaceutical composition is administered within 10 minutes of the onset of the first signs of an acute attack of familial hemiplegic migraine.

305. The method according to claim 282, wherein the pharmaceutical composition is administered within 30 minutes of the onset of the first signs of an acute attack of familial hemiplegic migraine.

306. The method according to claim 282, wherein the pharmaceutical composition is administered within one hour of the onset of the first signs of an acute attack of familial hemiplegic migraine.

307. The method according to claim 282, wherein the pharmaceutical composition is administered within two hours of the onset of the first signs of an acute attack of familial hemiplegic migraine.

308. The method according to claim 282, wherein the pharmaceutical composition is administered within four hours of the onset of the first signs of an acute attack of familial hemiplegic migraine.

309. The method according to claim 282, further comprising administering a second dose of the pharmaceutical composition at least 90 minutes after the first dose.

310. The method according to claim 309, wherein no more than two doses are administered within 24 hours.

311. The method according to claim 282, wherein the subject is free from headache pain within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

312. The method according to claim 282, wherein the subject experiences a reduction in headache pain within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

313. The method according to claim 282, wherein the subject experiences a reduction in photophobia within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

314. The method according to claim 282, wherein the subject experiences a reduction in phonophobia within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

315. The method according to claim 282, wherein the subject experiences a reduction in nausea within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

316. The method according to claim 282, wherein the subject does not experience headache pain for more than two hours after administration.

317. The method according to claim 282, wherein the subject is free from hemiplegia within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

318. The method according to claim 282, wherein the subject experiences a reduction in hemiplegia of the arm within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

319. The method according to claim 282, wherein the subject experiences a reduction in leg hemiplegia within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

320. A method for treating sporadic hemiplegic migraine, comprising administering a pharmaceutical composition comprising at least one minor cannabinoid, CBD, and THC to a subject requiring such treatment.

321. The method according to claim 320, wherein the subject is male.

322. The method according to claim 320, wherein the subject is a human.

323. The method according to claim 320, wherein administration is achieved by injection.

324. The method according to claim 320, wherein the treatment is effective within at least two hours after administration.

325. The method according to claim 320, wherein the pharmaceutical composition further comprises a terpenoid.

326. The method according to claim 325, wherein the terpenoid comprises myrcene, β-caryophyllene, limonene, α-terpineol, linalool, α-phellandrene, α-pinene, β-pinene, γ-terpinene, nerolidol, phytol, caryophyllene oxide, or α-humul.

327. The method according to claim 320, wherein the pharmaceutical composition further comprises an analgesic.

328. The method according to claim 327, wherein the analgesic comprises paracetamol, acetaminophen, a nonsteroidal anti-inflammatory drug, a 5-HT (serotonin) receptor agonist, a calcitonin gene-related peptide (CGRP) receptor antagonist, a D-aspartate N-methyl (NMDA) inhibitor, a glutamate receptor antagonist, a substance P inhibitor, a GABA inhibitor, a FAAH inhibitor, a nerve growth factor (NGF) inhibitor, a brain-derived neurotrophic factor (BDNF) inhibitor, an extracellular signal-regulated kinase (ERK) antagonist, or an NO inhibitor.

329. The method according to claim 320, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

330. The method according to claim 329, wherein the pharmaceutically acceptable excipients include carriers, diluents, binders, fillers, buffers, pH modifiers, disintegrants, dispersants, preservatives, lubricants, taste masking agents, fragrances, or colorants.

331. The method according to claim 320, wherein the purity of THC and CBD is at least 90% by weight.

332. The method according to claim 320, wherein the pharmaceutical composition further comprises at least one minor cannabinoid.

333. The method according to claim 332, wherein at least one minor cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.

334. The method according to claim 332, wherein the purity of at least one minor cannabinoid is at least 90% by weight.

335. The method according to claim 320, wherein the weight ratio of CBD to THC is approximately 50:1 to approximately 150:

1.

336. The method according to claim 320, wherein the weight ratio of CBD to THC is approximately 75:1 to approximately 125:

1.

337. The method according to claim 320, wherein the pharmaceutical composition is administered when the patient develops the first signs of an acute attack of sporadic hemiplegic migraine.

338. The method according to claim 320, wherein the pharmaceutical composition is administered within 5 minutes of the onset of the first signs of an acute attack of sporadic hemiplegic migraine.

339. The method according to claim 320, wherein the pharmaceutical composition is administered within 10 minutes of the onset of the first signs of an acute attack of sporadic hemiplegic migraine.

340. The method according to claim 320, wherein the pharmaceutical composition is administered within 30 minutes of the onset of the first signs of an acute attack of sporadic hemiplegic migraine.

341. The method according to claim 320, wherein the pharmaceutical composition is administered within one hour of the onset of the first signs of an acute attack of sporadic hemiplegic migraine.

342. The method according to claim 320, wherein the pharmaceutical composition is administered within two hours of the onset of the first signs of an acute attack of sporadic hemiplegic migraine.

343. The method according to claim 320, wherein the pharmaceutical composition is administered within four hours of the onset of the first signs of an acute attack of sporadic hemiplegic migraine.

344. The method according to claim 320, further comprising administering a second dose of the pharmaceutical composition at least 90 minutes after the first dose.

345. The method according to claim 344, wherein no more than two doses are administered within 24 hours.

346. The method according to claim 320, wherein the subject is free from headache pain within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

347. The method according to claim 320, wherein the subject experiences a reduction in headache pain within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

348. The method according to claim 320, wherein the subject experiences a reduction in photophobia within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

349. The method according to claim 320, wherein the subject experiences a reduction in phonophobia within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

350. The method according to claim 320, wherein the subject experiences a reduction in nausea within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

351. The method according to claim 320, wherein the subject does not experience headache pain for more than two hours after administration.

352. The method according to claim 320, wherein the subject is free from hemiplegia within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

353. The method according to claim 320, wherein the subject experiences a reduction in hemiplegia of the arm within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

354. The method according to claim 320, wherein the subject experiences a reduction in leg hemiplegia within 15 minutes, 30 minutes, 1 hour, 4 hours, 24 hours, or 48 hours after administration.

355. A method for alleviating the severity of hemiplegic migraine, comprising administering a pharmaceutical composition containing CBD and THC to a subject in need thereof.

356. A method for reducing the duration of hemiplegic migraine, comprising administering a pharmaceutical composition containing CBD and THC to a subject in need thereof.

357. A method for reducing the frequency of hemiplegic migraine attacks, comprising administering a pharmaceutical composition containing CBD and THC to a subject in need thereof.

358. A method for reducing the severity of symptoms of hemiplegic migraine, comprising administering a pharmaceutical composition containing CBD and THC to a subject in need thereof.

359. A method for preventing the onset of symptoms of hemiplegic migraine, comprising administering a pharmaceutical composition containing CBD and THC to a subject in need before the onset of symptoms of hemiplegic migraine.

360. The method according to claim 359, wherein the composition is administered at least one hour before the onset of symptoms of hemiplegic migraine.

361. The method according to claim 359, wherein the composition is administered at least 30 minutes before the onset of symptoms of hemiplegic migraine.

362. The method according to claim 359, wherein the composition is administered up to 15 minutes before the onset of symptoms of hemiplegic migraine.

363. The method according to claim 359, wherein the composition is administered up to 10 minutes before the onset of symptoms of hemiplegic migraine.

364. The method according to claim 359, wherein the composition is administered up to 5 minutes before the onset of symptoms of hemiplegic migraine.

365. The method according to any one of the above claims, further comprising confirming the target hemiplegic migraine genotype before administering the pharmaceutical composition.

366. A method for treating epilepsy, comprising administering a pharmaceutical composition containing CBD and THC to a subject in need before the onset of symptoms of hemiplegic migraine.

367. A method for preventing the onset of symptoms of epilepsy, comprising administering a pharmaceutical composition containing CBD and THC to a subject in need before the onset of symptoms of hemiplegic migraine.

Images